Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea, Aug. 28, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS) today announced a rights offering to…
SK Hynix Stock Spikes 14% in Hugely Anticipated US Market Debut
The memory trade has hit a few speed bumps lately, but that didn’t stop investors from flocking to…
Failed SpaceX IPO allocation prompts Korea to widen Mirae review
South Korea’s financial watchdog has expanded an inspection of Mirae Asset Securities Co. to examine the brokerage’s failure…